Guided Therapeutics Statistics
Guided Therapeutics (GTHP) Stock Statistics & Valuation Metrics
Total Valuation
Guided Therapeutics has a market cap or net worth of $9.65M. The enterprise value is $24.66T.
- Market Cap
- $9.65M
- Enterprise Value
- $24.66T
Share Statistics
Guided Therapeutics has 96,537,346 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 96,537,346
- Owned by Insiders
- 36.94%
- Owned by Institutions
- ―
Financial Efficiency
Guided Therapeutics’s return on equity (ROE) is 0.53 and return on invested capital (ROIC) is 77.34%.
- Return on Equity (ROE)
- 0.53
- Return on Assets (ROA)
- -2.41
- Return on Invested Capital (ROIC)
- 77.34%
- Return on Capital Employed (ROCE)
- 0.45
- Revenue Per Employee
- 255.67K
- Profits Per Employee
- -1.07M
- Employee Count
- 3
- Asset Turnover
- 0.58
- Inventory Turnover
- 0.44
Valuation Ratios
The current PE Ratio of Guided Therapeutics is -2.75. Guided Therapeutics’s PEG ratio is -1.16.
- PE Ratio
- -2.75
- PS Ratio
- 16.34
- PB Ratio
- -1.84
- Price to FCF
- -7.05
- Price to Operating Cash Flow
- -7.06
- PEG Ratio
- -1.16
Income Statement
In the last 12 months, Guided Therapeutics had revenue of 767.00K and earned -3.20M in profits. Earnings per share was -0.04.
- Revenue
- 767.00K
- Gross Profit
- 571.00K
- Operating Income
- -2.37M
- Pretax Income
- -3.20M
- Net Income
- -3.20M
- EBITDA
- -2.47M
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was -1.50M and capital expenditures -2,000, giving a free cash flow of -1.51M billion.
- Operating Cash Flow
- -1.50M
- Free Cash Flow
- -1.51M
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Guided Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.30%
- Earnings Yield
- -27.96%
Stock Price Statistics
- Beta
- 1.78
- 52-Week Price Change
- -60.00%
- 50-Day Moving Average
- 0.20
- 200-Day Moving Average
- 0.25
- Relative Strength Index (RSI)
- 34.92
- Average Volume (3m)
- 47.28K
Financial Position
Guided Therapeutics as a current ratio of 0.09, with Debt / Equity ratio of -48.93%
- Current Ratio
- 0.09
- Quick Ratio
- 0.02
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- -1.16
- Interest Coverage Ratio
- -3.84
Taxes
In the past 12 months, Guided Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Guided Therapeutics EV to EBITDA ratio is -6.33, with an EV/FCF ratio of -10.69.
- EV to Sales
- 24.76
- EV to EBITDA
- -6.33
- EV to Free Cash Flow
- -10.69
- EV to Operating Cash Flow
- -10.70
Balance Sheet
Guided Therapeutics has $12.00K in cash and marketable securities with $2.79M in debt, giving a net cash position of -$2.77M billion.
- Cash & Marketable Securities
- $12.00K
- Total Debt
- $2.79M
- Net Cash
- -$2.77M
- Net Cash Per Share
- -$0.03
- Tangible Book Value Per Share
- -$0.06
Margins
Gross margin is 64.00%, with operating margin of -337.23%, and net profit margin of -573.08%.
- Gross Margin
- 64.00%
- Operating Margin
- -337.23%
- Pretax Margin
- -471.23%
- Net Profit Margin
- -573.08%
- EBITDA Margin
- -390.92%
- EBIT Margin
- -406.77%
Analyst Forecast
The average price target for Guided Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- 450.85%
- EPS Growth Forecast
- -1.21%
